45 citations
,
September 2000 in “Archives of dermatology” The study found that the enzyme linked to acne is present in the same areas of both acne-affected and normal skin.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
25 citations
,
February 2014 in “British journal of dermatology/British journal of dermatology, Supplement” Intralesional triamcinolone acetonide can regrow hair in alopecia areata but often has temporary effects and side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
1 citations
,
January 2010 in “Serbian Journal of Dermatology and Venereology” The document concludes that effective acne treatment requires a personalized combination of therapies and long-term commitment, with retinoids being important for maintenance.
31 citations
,
July 2012 in “Journal of Lipid Research” ACBP is crucial for healthy skin in mice.
14 citations
,
January 2015 in “Acta dermato-venereologica” Acitretin significantly reduced inflammatory attacks in a woman with Naevus Comedonicus Syndrome but caused side effects.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
30 citations
,
April 2007 in “Dermatologic Clinics” The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
August 2025 in “İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi” The method accurately measures vitamin E compounds in capsules.
36 citations
,
February 2007 in “Journal of biological chemistry/The Journal of biological chemistry” The vitamin D receptor can work without its usual activating molecule.
12 citations
,
May 2017 in “Medicine” Oral isotretinoin was recommended for a 21-year-old woman with severe acne.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
September 2020 in “Journal of Education, Health and Sport” Most patients on isotretinoin for acne experience mild, dose-related side effects, but the connection to depression or bowel disease is uncertain.
5 citations
,
February 2018 in “Military medicine” A U.S. Naval fighter pilot suffered permanent vision loss in one eye due to recurrent central serous retinopathy.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
11 citations
,
October 1990 in “The Journal of dermatologic surgery and oncology” New treatments for skin aging will soon compete with current ones like tretinoin.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
July 1995 in “Journal of Dermatological Science”
20 citations
,
December 2011 in “Journal of inherited metabolic disease” Valproic acid treatment increases a specific acid in urine by blocking an enzyme, possibly causing skin rash and hair loss.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
2 citations
,
August 2019 in “PubMed” A specific enzyme that activates the hair growth medication minoxidil when applied to the skin was identified.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
34 citations
,
June 1990 in “British Journal of Dermatology” Etretinate treatment changed hair growth patterns in many patients.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.